Skip to main content
TipRanks
Go Ultimate75% OFF

Elicera Therapeutics AB (8E8) AI Stock Analysis

0 Followers
DE:8E8

Elicera Therapeutics AB

(Frankfurt:8E8)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Debt-free balance sheetA debt-free balance sheet reduces refinancing and interest obligations, giving Elicera greater flexibility while it advances its pipeline. This financial structure can help preserve strategic options and limit creditor pressure, although it does not remove the need to fund ongoing operations.
Negative Factors
No current TTM revenueThe absence of TTM revenue shows that Elicera currently lacks a recurring commercial revenue base to fund operations. The decline from prior reported revenue also indicates that near-term financial support depends primarily on successful development, licensing, partnering, or additional capital.

Elicera Therapeutics AB (8E8) vs. iShares MSCI Germany ETF (EWG)

-80%-60%-40%-20%0%20%40%DE:8E8-54.91%EWG+9.37%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 15.54M
Dividend Yield
―
Average Volume (3M)
1,000
Price to Earnings (P/E)
-7.3
Beta (1Y)
0.82
Revenue Growth
―
EPS Growth
10.71%
Country
Germany
Employees
3
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Elicera Therapeutics AB Business Overview & Revenue Model

Company Description

Elicera Therapeutics AB (publ), a Swedish immuno-oncology firm founded in Göteborg in 2014, is dedicated to the clinical development of cell and gene therapies that harness the immune system to combat cancer. Its promising pipeline features several d...

Elicera Therapeutics AB Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:8E8 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SE:CANTASE:CANTA61NeutralSEK 391.34M2.0463.09%―――
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
SE:BINVSE:BINV49NeutralSEK 191.82M-0.39-128.54%―-83.67%-50.29%
SE:ONCOSE:ONCO44NeutralSEK 763.50M-2.81――65.37%43.28%
SE:ATORXSE:ATORX39UnderperformSEK 32.47M-0.01-439.98%―-99.33%64.90%
SE:IMMUSE:IMMU39UnderperformSEK 276.26M-2.43-19.14%――13.06%

* Healthcare Sector Average

Performance Comparison

-50%0%50%DE:8E8SE:ATORXSE:BINVSE:ONCOSE:IMMUSE:CANTADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:8E8 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:8E8Elicera Therapeutics AB0.20-0.26-55.90%
SE:ATORXAlligator Bioscience AB0.01-0.19-95.05%
SE:BINVBioInvent International AB2.92-26.98-90.25%
SE:ONCOOncopeptides AB1.77-3.13-63.86%
SE:IMMUImmunicum AB4.36-1.30-23.06%
SE:CANTACantargia AB1.39-2.06-59.77%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.